15 Jul 2021 10:28
15 July 2021
Midatech Pharma PLC
("Midatech" or the "Company")
Grant of Options
PDMR dealings
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines announces that options over a total of 1,924,000 ordinary shares of 0.1 pence each in the capital Company have been granted to employees under the 2014 Midatech Pharma plc Enterprise Management Incentive Scheme ("Options").
Of these Options, 750,000 in aggregate have been granted to two executives designated as PDMRs; Stephen Stamp, Chief Executive Officer, Chief Financial Officer and director of the Company and Dmitry Zamoryakhin, Chief Scientific Officer resulting in them having the following interests in the Company:
Director | Award of Options | Resulting interest in options | Current shareholding in the Company |
Stephen Stamp - Chief Executive Officer, Chief Financial Officer | 500,000 | 830,000 | 50,000 |
Dmitry Zamoryakhin - Chief Scientific Officer | 250,000 | 250,000 | - |
The Options have an exercise price of 27.75 pence per share, being the mid-market closing price on 14 July 2021. The Options will vest 25% upon the one year anniversary of grant, with the remainder vesting in 12 equal tranches quarterly over the following three years. Once vested, the options will be exercisable until 14 June 2031.
The Options granted represent 1.95 per cent. of the issued share capital.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Stephen Stamp | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Executive Officer, Chief Financial Officer | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Midatech Pharma plc | |||
b)
| LEI
| 549300GKR2G40H3QFY57 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Options over Ordinary shares of 0.1 pence each in Midatech Pharma plc | |||
Identification code | GB00BKT14T00 | ||||
b)
| Nature of the transaction
| Grant of Options over Ordinary shares
| |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
27.75p | 500,000 |
| |||
d)
| Aggregated information | ||||
- Aggregated volume | As above | ||||
- Price | |||||
e)
| Date of the transaction
| 15 June 2021 | |||
f)
| Place of the transaction
| Off market transaction | |||
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Dmitry Zamoryakhin | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Scientific Officer | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Midatech Pharma plc | |||
b)
| LEI
| 549300GKR2G40H3QFY57 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Options over Ordinary shares of 0.1 pence each in Midatech Pharma plc | |||
Identification code | GB00BKT14T00 | ||||
b)
| Nature of the transaction
| Grant of Options over Ordinary shares
| |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
27.75 p | 250,000 |
| |||
d)
| Aggregated information | ||||
- Aggregated volume | As above | ||||
- Price | |||||
e)
| Date of the transaction
| 15 June 2021 | |||
f)
| Place of the transaction
| Off market transaction | |||
For more information, please contact:
Midatech Pharma PLC |
Stephen Stamp, CEO, CFO |
Tel: +44 (0)29 2048 0180 |
www.midatechpharma.com |
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) |
Freddy Crossley, Emma Earl (Corporate Finance) |
Rupert Dearden (Corporate Broking) |
Tel: +44 (0)20 7886 2500 |
Turner Pope Investments (TPI) Limited (Joint Broker) |
Andrew Thacker / James Pope (Corporate Broking) Tel: +44(0)20 3657 0050
|
IFC Advisory Limited (Financial PR and UK Investor Relations) |
Tim Metcalfe / Graham Herring |
Tel: +44 (0)20 3934 6630 |
Email: midatech@investor-focus.co.uk |
Edison Group (US Investor Relations) Maxwell Colbert Tel: +1 (646) 653 7028 Email: mcolbert@edisongroup.com
|